IDEMIA: French biometric solutions MNC sets up APAC headquarters in Singapore
From seamless airport immigration clearance to secure contactless payments to secure electronic voting – IDEMIA's technology empowers citizens and consumers to interact, pay, connect, travel, and vote safely in an increasingly digital world.
With its advanced biometric and identity security solutions, IDEMIA enables governments and businesses to provide safer, more efficient services through innovative payment systems, border control solutions, and identity verification technologies.
The Singapore office serves as IDEMIA's APAC headquarters, driving sales, delivery and support across the region. Additionally, the company will expand its R&D capabilities here, focusing on solutions for identification, border control, road safety, and public security.
IDEMIA plans to leverage Singapore's innovation ecosystem to develop new solutions for the region and potentially global markets through its local R&D centre. Singapore's vibrant digital ecosystem and strategic position supporting APAC markets made it an ideal choice for IDEMIA's regional headquarters. This expansion will strengthen the company's presence in Asia, and it hopes to contribute to Singapore's development as a leading digital security hub.
Gene Solutions: Biotech pioneer in genetic testing establishes regional hub in Singapore
A simple blood test that can detect cancer early or help expectant parents understand their baby's health – these are some of the genetic testing services that Gene Solutions is making accessible across Southeast Asia.
The Vietnam-founded biotechnology pioneer has established its regional hub for clinical oncology testing and development in Singapore, marking a significant step in its mission to revolutionise healthcare through advanced genomics and AI.
With over 2 million tests provided to patients and families in the region, Gene Solutions specialises in next-generation genetic testing, such as Non-invasive Prenatal Testing (NIPT) and clinical oncology solutions. Their Singapore hub will house a state-of-the-art laboratory, accredited by the US College of American Pathology, focusing on clinical oncology testing and innovative solutions that combine genomic science with artificial intelligence capabilities.
Singapore's robust capital markets environment and collaborative healthcare ecosystem made it a natural choice for Gene Solutions’ expansion. Between 2022 and 2024, startups in the healthcare sector closed 67 deals with a cumulative value of US$0.97 billion (S$1.3 billion), despite the recent global downturn in biotech investments2. In addition, Singapore’s deep pool of biomedical talent and strong network of research institutes will support the company's R&D ambitions and provide opportunities to forge strategic partnerships across the region.
Through this new centre, Gene Solutions aims to further its mission of making advanced genetic testing more accessible throughout Southeast Asia.